Ruxolitinib Cream Reduced Skin Lesions in GVHD Trial
A new clinical study found that topical ruxolitinib improved skin symptoms in patients with graft-versus-host disease.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you believe new medical treatments should be preferred over traditional standard care methods?
A clinical trial published in The Lancet Haematology demonstrated that applying 1.5% ruxolitinib cream twice daily significantly reduces skin lesion surface area in chronic graft-versus-host disease patients. The study showed a notable improvement for participants compared to a control group over a 28-day treatment period.
Why it matters
Chronic graft-versus-host disease, which affects roughly 50% of allogeneic hematopoietic stem cell transplant recipients, often proves difficult to manage with standard therapies. This research offers a potential new topical intervention for the skin-related complications of the condition.
In a 24-patient study with a mean age of 47.5, the treatment group reduced mean affected skin surface area from 14.3% to 6.2%, while the control group went from 14.5% to 10.4%. No severe adverse effects were reported during the trial.
The players
Cornell University
This institution served as the research site where the team conducted the clinical trial on topical ruxolitinib.
The Lancet Haematology
This peer-reviewed medical journal published the findings of the clinical trial regarding graft-versus-host disease treatments.
The details
Researchers at Cornell University tested the efficacy of 1.5% ruxolitinib, a Janus kinase 1 and 2 inhibitor, by having patients apply the cream to affected areas twice daily. The treatment demonstrated an adjusted 4 percentage point difference in affected body surface area reduction compared to the control group.
Timeline
The topical treatment was applied by participants for a total duration of 28 days.
The Big Picture
This research follows the established trajectory of using Janus kinase inhibitors to treat complex inflammatory conditions. It marks a departure from systemic treatments by focusing on the localized application of ruxolitinib for skin-specific manifestations of graft-versus-host disease.
Patients suffering from skin-related graft-versus-host disease may eventually have access to a topical cream that avoids the side effects of systemic therapies. This development could change daily health routines for transplant recipients by providing a targeted, non-invasive treatment option.
The takeaway
Topical ruxolitinib shows promise as a localized treatment for the common skin symptoms associated with chronic graft-versus-host disease. Patients should consult their transplant specialists to discuss emerging treatment options as new data becomes available.
Further reading
For more information on the latest research in this field, visit the Cancer section.
Live Poll
Do you believe new medical treatments should be preferred over traditional standard care methods?
